Novolog (Pharm UP 1966) Ltd. (IL:NVLG)
TASE:NVLG
NVLG Stock Chart & Stats
126.20
>-0.01(-0.31%)
At close: 4:00 PM EST
126.20
>-0.01(-0.31%)
Day’s Range― - ―
52-Week Range91.20 - 155.34
Previous CloseN/A
Volume351.22K
Average Volume (3M)641.09K
Market Cap
₪522.11M
Enterprise Value590.19M
Total Cash (Recent Filing)₪121.77M
Total Debt (Recent Filing)₪183.20M
Price to Earnings (P/E)155.9
Beta0.69
Next Earnings
May 20, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend Yield3.05%
Share Statistics
EPS (TTM)0.80
Shares Outstanding510,874,760
10 Day Avg. Volume285,794
30 Day Avg. Volume641,093
Financial Highlights & Ratios
PEG Ratio-1.74
Price to Book (P/B)1.80
Price to Sales (P/S)0.36
P/FCF Ratio-18.75
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance-sheet ResilienceA roughly 0.5x debt-to-equity provides structural financial flexibility versus highly leveraged peers. This lower leverage supports refinancing capacity, cushions shocks from cyclical revenue swings, and preserves room for strategic investment or working-capital support over coming quarters.
Proven Cash-generation CapabilityHistoric ability to convert earnings into substantial operating and free cash flow demonstrates the underlying business can generate liquidity when operations normalize. That track record implies the firm can rebuild cash buffers and service debt once revenue and margins recover.
Structural Industry DemandOperating in medical care facilities exposes the company to long-term demographic tailwinds and recurring demand for care services. Structural aging-population trends and essential-service characteristics support steadier revenue baselines and less cyclicality than discretionary sectors.
Bears Say
Revenue And Earnings DeclineA sharp year-over-year revenue drop and collapse in net income signal durable demand or competitive pressure issues. Such declines erode operating leverage, strain margins and can persist if market share or pricing power were lost, making recovery of prior profitability uncertain.
Negative Cash Flow In 2025A reversal to negative operating and free cash flow materially increases funding risk and reduces internal ammunition for reinvestment or dividends. If cash generation remains weak over multiple quarters, the company may require external financing or asset sales, weakening strategic optionality.
Volatile Earnings HistoryRepeated swings in profitability, including a prior loss and the recent collapse, indicate unstable margin drivers or exposure to variable reimbursement/pricing environments. Persistent volatility complicates planning, raises investor and creditor risk premiums, and undermines predictable cash returns.
Novolog News
NVLG FAQ
What was Novolog (Pharm UP 1966) Ltd.’s price range in the past 12 months?
Novolog (Pharm UP 1966) Ltd. lowest stock price was 91.20 and its highest was 155.34 in the past 12 months.
What is Novolog (Pharm UP 1966) Ltd.’s market cap?
Novolog (Pharm UP 1966) Ltd.’s market cap is ₪522.11M.
When is Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date?
Novolog (Pharm UP 1966) Ltd.’s upcoming earnings report date is May 20, 2026 which is in 42 days.
How were Novolog (Pharm UP 1966) Ltd.’s earnings last quarter?
Novolog (Pharm UP 1966) Ltd. released its earnings results on Nov 12, 2025. The company reported 0.8 earnings per share for the quarter, beating the consensus estimate of N/A by 0.8.
Is Novolog (Pharm UP 1966) Ltd. overvalued?
According to Wall Street analysts Novolog (Pharm UP 1966) Ltd.’s price is currently Overvalued.
Does Novolog (Pharm UP 1966) Ltd. pay dividends?
Novolog (Pharm UP 1966) Ltd. pays a Quarterly dividend of 1.957 which represents an annual dividend yield of 3.05%. See more information on Novolog (Pharm UP 1966) Ltd. dividends here
What is Novolog (Pharm UP 1966) Ltd.’s EPS estimate?
Novolog (Pharm UP 1966) Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Novolog (Pharm UP 1966) Ltd. have?
Novolog (Pharm UP 1966) Ltd. has 510,874,760 shares outstanding.
What happened to Novolog (Pharm UP 1966) Ltd.’s price movement after its last earnings report?
Novolog (Pharm UP 1966) Ltd. reported an EPS of 0.8 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Novolog (Pharm UP 1966) Ltd.?
Currently, no hedge funds are holding shares in IL:NVLG
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Novolog (Pharm UP 1966) Ltd.
Novolog (Pharm-Up 1966) Ltd provides healthcare services in Israel. It offers medical devices to healthcare institutions and patients in their homes; and medical logistics services to pharmaceutical and medical device companies. The company also produces and disseminates medical content and tools to the general public and medical community; and develops personalized treatment programs and initiates home visits by nurses. In addition, it provides health and medical process management services for corporations; and supplies sterilization services using ethylene oxide gas for medical and laboratory products, as well as offers direct access to health and wellness ecosystem for international corporations. The company is based in Modi'in-Maccabim-Re'ut, Israel.